Real-world data of China: Analysis of HPV vaccine coverage and post-vaccination adverse reaction monitoring in Western Chinese provinces from 2018 to 2021

Jing An,Yan Liu,Yingchun Ma,Yong-Zhuo Jiao,Xue-Feng Liang,Na Jin,Junyi Bao,Nan Jiang,Xiao-Shu Zhang

DOI: https://doi.org/10.1080/21645515.2024.2315653

2024-02-20

Human Vaccines & Immunotherapeutics

Abstract:To investigate the HPV vaccine coverage and post-vaccination adverse reactions in Gansu Province, Western China, from 2018 to 2021. Data on suspected adverse reactions to HPV vaccines were collected from the Chinese Vaccine Adverse Event Following Immunization (AEFI). Estimate the incidence rates of Common Adverse Reaction and Rare Adverse Reaction. HPV vaccine coverage among females in different age groups was calculated using data from the Gansu Provincial Immunization Information Platform. The first-dose HPV vaccine coverage rate among females aged 9 to 45 was 2.02%, with the lowest rate of less than 1% observed in females aged 9 to 14. From 2018 to 2021, the incidence rates of Common Adverse Reaction and Rare Adverse Reaction reported in females after HPV vaccination were 11.82 and 0.39 per 100,000 doses, respectively. Common Adverse Reaction included fever (5.52 per 100,000 doses), local redness and swelling (3.33 per 100,000 doses), fatigue (3.15 per 100,000 doses), headache (2.76 per 100,000 doses), as well as local induration and nausea/vomiting (1.97 per 100,000 doses). Adverse reactions mainly occurred within 1 day after vaccination, followed by 1 to 3 days after vaccination. The HPV vaccine coverage rate among females aged 9 to 14 in Gansu Province is remarkably low, and there is an urgent need to enhance vaccine coverage. From 2018 to 2021, the incidence of Adverse reaction Following Immunization HPV vaccination fell within the expected range, indicating the vaccine's safety profile.

immunology,biotechnology & applied microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the low vaccination coverage rate of human papillomavirus (HPV) vaccine and the monitoring of adverse reactions after vaccination in western China (taking Gansu province as an example). Specifically, the study focused on the HPV vaccination rates of women in different age groups in Gansu province from 2018 to 2021, as well as the occurrence of common and rare adverse reactions after vaccination. By analyzing real - world data, the study aims to provide basic information to support future efforts to increase the HPV vaccination rate and contribute to the goal of eliminating cervical cancer.

### Main problems:
1. **HPV vaccination coverage rate**:
- The study analyzed the HPV vaccination rates of women aged 9 to 45 in Gansu province from 2018 to 2021.
- Special attention was paid to the vaccination rate of women aged 9 to 14, which is considered the best vaccination period for preventing cervical cancer.

2. **Monitoring of adverse reactions after vaccination**:
- Collected and analyzed the suspected adverse events following immunization (AEFI) reported in Gansu province after HPV vaccination from 2018 to 2021.
- Evaluated the incidence rates of common adverse reactions (such as fever, local redness and swelling, fatigue, headache, etc.) and rare adverse reactions.

### Background information:
- Cervical cancer is the fourth most common malignant tumor among women worldwide, with approximately 570,000 new cases and 270,000 deaths each year.
- The incidence and mortality rates of cervical cancer in China are relatively high, especially in western regions such as Gansu province, where the standardized incidence and mortality rates are 1.34 times and 1.62 times the national average, respectively.
- The HPV vaccine is an effective measure to prevent cervical cancer, but as of 2021, the HPV vaccination rate in China is far lower than that in developed countries and regions.

### Research purposes:
- **Understand the current situation**: By analyzing real - world data, understand the HPV vaccination rates of women in different age groups in Gansu province.
- **Evaluate safety**: Monitor and evaluate the adverse reactions after HPV vaccination to ensure the safety of the vaccine.
- **Provide basis**: Provide a scientific basis for increasing the HPV vaccination rate in the future and achieving the goal of eliminating cervical cancer.

### Methods:
- **Data sources**: Obtain HPV vaccination and adverse reaction data from 2018 to 2021 from the Gansu provincial immunization information system and the national AEFI information management system.
- **Statistical analysis**: Calculate the first - time vaccination rates and adverse reaction incidence rates in different age groups, and use R software for data analysis.

### Results:
- **Vaccination rate**: From 2018 to 2021, a total of 253,759 doses of HPV vaccine were vaccinated in Gansu province. Among them, the first - time vaccination rate of women aged 9 to 45 was 2.02%, and the lowest was for women aged 9 to 14, with a vaccination rate of less than 1%.
- **Adverse reactions**: A total of 33 cases of AEFI were reported, of which 31 were common adverse reactions and 1 was a rare adverse reaction. Common adverse reactions mainly included fever, local redness and swelling, fatigue, headache, etc., and the rare adverse reaction was non - cardiogenic chest pain.

### Discussion:
- **Reasons for low vaccination rate**:
- Insufficient vaccine supply.
- Influence of parents' wishes and recommendations from vaccination clinics.
- Insufficient public awareness of quadrivalent and nonavalent HPV vaccines.
- **Safety**: The research results show that the incidence rate of adverse reactions of HPV vaccine in Gansu province is within the expected range, indicating that the vaccine is safe.

Through these analyses, the study provides an important reference basis for increasing the HPV vaccination rate and protecting women's health.